{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CLPBF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLPBF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLPBF\",,,,,undefined,":{"symbol":"CLPBF","market":"US","secType":"STK","nameCN":"Coloplast AS","latestPrice":99.05,"timestamp":1747146300000,"preClose":99.05,"halted":0,"volume":0,"delay":15,"floatShares":141989600,"shares":224840059,"eps":3.239627,"marketStatus":"Trading","change":0,"latestTime":"05-13 10:25:00 EDT Delay","open":99.05,"high":99.05,"low":99.05,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":3.239627,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1747166400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":99.05,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLPBF\",,,,,undefined,":{"symbol":"CLPBF","floatShares":141989600,"roa":"9.64%","roe":"27.42%","lyrEps":3.149522,"shares":224840059,"dividePrice":3.237828,"high":99.05,"amplitude":0,"preClose":99.05,"low":99.05,"week52Low":96.68,"pbRate":"8.93","psRate":"5.44","week52High":140.315,"institutionHeld":0,"latestPrice":99.05,"eps":3.239627,"divideRate":0.032689,"volume":0,"delay":15,"ttmEps":3.239627,"open":99.05,"prevYearClose":108.281,"prevWeekClose":99.05,"prevMonthClose":106.31,"prevQuarterClose":104.15,"fiveDayClose":106.25,"twentyDayClose":98.61,"sixtyDayClose":110.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLPBF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532073717","title":"Coloplast A/S Revised guidance for FY 2024/25","url":"https://stock-news.laohu8.com/highlight/detail?id=2532073717","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532073717?lang=en_us&edition=fundamental","pubTime":"2025-05-01 18:23","pubTimestamp":1746094980,"startTime":"0","endTime":"0","summary":"Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures. Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024/25. The organic growth is now expected to be around 7%, from previously 8-9%. The EBIT margin before special items is now expected to be 27-28%, from previously around 28%.Group organic growth was 6% in Q2. The EBIT margin before special items was 27%.Organic growth rates by business area: Ostomy Care 4%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 10% and Interventional Urology -1%.The slower growth in Ostomy Care was due to a high baseline in Europe, tender phasing in Emerging markets and a slow-down in China. Growth in Ostomy Care is expected to pick up in the second half of the year compared to Q2.Voice and Respiratory Care growth was driven by both Laryngectomy and Tracheostomy, against a high baseline last year.Special Items are now expected to be around ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coloplast-revised-guidance-fy-2024-102300730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLPBF","CLPBY","BK4198"],"gpt_icon":0},{"id":"2527841345","title":"Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST","url":"https://stock-news.laohu8.com/highlight/detail?id=2527841345","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527841345?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:05","pubTimestamp":1744718700,"startTime":"0","endTime":"0","summary":"Tuesday, 6 May 2025 at 11.00 - 12.00am CESTIn connection with the publication of Coloplast’s interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the event.Coloplast will be represented by: Kristian Villumsen-President & CEOAnders Lonning-Skovgaard-Executive Vice President, CFOAleksandra Dimovska - Vice President, Investor RelationsSimone Dyrby Helvind - Senior Manager, Investor Relations. WebcastFor participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below:Access the webcast here. Dial-in detailsTo actively participate in the Q&A session, please sign up ahead of the confer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coloplast-h1-2024-25-earnings-120500728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLPBY","CLPBF"],"gpt_icon":0},{"id":"2509332420","title":"Coloplast AS (CLPBF) Q1 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2509332420","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509332420?lang=en_us&edition=fundamental","pubTime":"2025-02-05 15:04","pubTimestamp":1738739042,"startTime":"0","endTime":"0","summary":"EBIT Margin Before Special Items: 27% in Q1.Revenue Increase: DKK420 million or 6% compared to last year.Gross Margin: 68%, on par with last year.Operating Profit Before Special Items: DKK1.9 billion, a 5% increase compared to last year.Net Profit Before Special Items: DKK1.4 billion, a 17% increase compared to last year.Adjusted Diluted Earnings Per Share: DKK6.38, a 17% increase.CapEx: DKK308 million with a CapEx to sales ratio of 4%.Advanced Wound Care Organic Growth: 12% in Q1.Voice and Respiratory Care Growth: 11% in Q1.Effective Tax Rate: 41% due to extraordinary tax expense.GuruFocus has detected 4 Warning Signs with CLPBF.Coloplast AS  reported 8% organic growth and a 27% EBIT margin before special items, aligning with expectations.A: We don't run a perfect company, and we've had setbacks related to the distribution center and a quality problem in urology. We've addressed these issues, and the distribution center is back to service levels. We manufacture over 1.5 billion medica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coloplast-clpbf-q1-2025-earnings-070402410.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLPBY","CLPBF"],"gpt_icon":0},{"id":"2489646104","title":"Coloplast A/S - Decisions at the Annual General Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2489646104","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489646104?lang=en_us&edition=fundamental","pubTime":"2024-12-06 00:11","pubTimestamp":1733415060,"startTime":"0","endTime":"0","summary":"Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted:. The annual report for the financial year 2023/24 was approved.Distribution of year-end dividend of DKK 17.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2023/24 to DKK 22.00 per share of nominally DKK 1.The remuneration report for the financial year 2023/24 was approved.The remuneration of the members of the Board of Directors for the financial year 2024/25 was approved.Lars Sren Rasmussen, Niels Peter Louis-Hansen, Annette Brüls, Carsten Hellmann, Jette Nygaard-Andersen and Marianne Wiinholt were re-elected to the Board of Directors.Authorisation was granted to the chairman of the Annual General Meeting to make certain registrations with the Danish Business Authority and o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vtOyV58KsIYMzqeBgs6Kag--~B/aD0xMTgyO3c9MjQ3MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/133f9853fa5e77f27e2587159807b598","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vtOyV58KsIYMzqeBgs6Kag--~B/aD0xMTgyO3c9MjQ3MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/133f9853fa5e77f27e2587159807b598"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coloplast-decisions-annual-general-meeting-161100115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","BK4198","CVR","CLPBY","CLPBF"],"gpt_icon":0},{"id":"2488634162","title":"Coloplast divests core Skin Care product portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2488634162","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488634162?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:01","pubTimestamp":1733313660,"startTime":"0","endTime":"0","summary":"The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area.Revenue from the core Skin Care business amounted to around DKK 400 million in FY 2023/24, with an operating profitability level significantly below the group EBIT margin.Coloplast’s FY 2024/25 financial guidance1 of organic revenue growth at 8-9% and an EBIT margin before special items of around 28% is unchanged and already includes the divestment. This simplification of the portfolio will benefit the operating profitability of Advanced Wound Care and accounts for the majority of the around 30 basis points positive impact on the group EBIT margin as highlighted in the FY 2023/24 earnings release1.The divestment will reduce reported revenue for FY 2024/25 with around DKK 350 million, or around -1.5%-points impact on reported revenue growth.One-off items related to the divestment are included in the FY 2024/25 special items expectations of D","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vtOyV58KsIYMzqeBgs6Kag--~B/aD0xMTgyO3c9MjQ3MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/133f9853fa5e77f27e2587159807b598","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vtOyV58KsIYMzqeBgs6Kag--~B/aD0xMTgyO3c9MjQ3MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/133f9853fa5e77f27e2587159807b598"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coloplast-divests-core-skin-care-120100625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLPBF","CLPBY","BK4198"],"gpt_icon":0},{"id":"2481543218","title":"Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2481543218","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481543218?lang=en_us&edition=fundamental","pubTime":"2024-11-05 14:00","pubTimestamp":1730786400,"startTime":"0","endTime":"0","summary":"Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team  with immediate effect.Building an Advanced Wound Care business for the future“We have also invested to become a bigger player in Advanced Wound Care in both dressings and biologics. With our dressings business, our strategic priority is to strengthen our commercial focus and significantly improve profitability. With Kerecis, we are focused on delivering year two of our commercial plan and transitioning the business onto Coloplast’s IT infrastructure as the next step in building a biologics category leader. Our Advanced Wound Care business will be represented in the ELT once we have successfully concluded the Kerecis integration and have delivered on the profit improvement plans for the dressings business,” says Kristian Villumsen.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vtOyV58KsIYMzqeBgs6Kag--~B/aD0xMTgyO3c9MjQ3MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/133f9853fa5e77f27e2587159807b598","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vtOyV58KsIYMzqeBgs6Kag--~B/aD0xMTgyO3c9MjQ3MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/133f9853fa5e77f27e2587159807b598"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coloplast-announcement-no-05-2024-060000812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","BK4120","CLPBY","CLPBF","CVR","BK4198","TISI"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLPBF\",params:#limit:5,,,undefined,":[{"date":"2025-05-08","symbol":"CLPBF","amount":5,"announcedDate":"2025-05-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-09","defaultRemindTime":1746711000000,"name":"Coloplast AS","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-05-09","currency":"DKK","dateTimestamp":1746676800000,"payDate":"2025-05-12"},{"date":"2024-12-06","symbol":"CLPBF","amount":17,"announcedDate":"2024-11-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-09","defaultRemindTime":1733495400000,"name":"Coloplast AS","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-10","payableDate":"2024-12-09","currency":"DKK","dateTimestamp":1733461200000,"payDate":"2024-12-10"},{"date":"2024-05-13","symbol":"CLPBF","amount":5,"announcedDate":"2024-05-07","type":"dividend","market":"US","newRecordDate":"2024-05-14","defaultRemindTime":1715607000000,"name":"Coloplast AS","recordDate":"2024-05-15","payableDate":"2024-05-14","currency":"DKK","dateTimestamp":1715572800000,"payDate":"2024-05-15"},{"date":"2024-05-07","symbol":"CLPBF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715068800000,"name":null,"time":"","dateTimestamp":1715054400000,"actualEps":null},{"date":"2023-12-08","symbol":"CLPBF","amount":16,"announcedDate":"2023-11-09","type":"dividend","market":"US","newRecordDate":"2023-12-11","defaultRemindTime":1702045800000,"name":"Coloplast AS","recordDate":"2023-12-12","payableDate":"2023-12-11","currency":"DKK","dateTimestamp":1702011600000,"payDate":"2023-12-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLPBF\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-06","recordDate":"2018-12-07","paymentDate":"2018-12-10","value":11,"currency":"DKK"},{"executeDate":"2019-05-06","recordDate":"2019-05-07","paymentDate":"2019-05-08","value":5,"currency":"DKK"},{"executeDate":"2019-12-06","recordDate":"2019-12-09","paymentDate":"2019-12-10","value":12,"currency":"DKK"},{"executeDate":"2020-05-11","recordDate":"2020-05-12","paymentDate":"2020-05-13","value":5,"currency":"DKK"},{"executeDate":"2020-12-04","recordDate":"2020-12-07","paymentDate":"2020-12-08","value":13,"currency":"DKK"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLPBF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":2,"updateTime":1738296000000}}}